Skip to Content

LifeMD, Inc.

Securities Class Action

  • Date:
  • 10/27/2025
  • Company Name:
  • LifeMD, Inc.
  • Stock Symbol:
  • LFMD
  • Class Period:
  • FROM 5/7/2025 TO 8/5/2025
  • Status:
  • Filed
  • Filing Date:
  • 8/27/2025
  • Court:
  • U.S. District Court: Eastern District of New York

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ:LFMD) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired LifeMD securities between May 7, 2025 and August 5, 2025, both dates inclusive (the “Class Period”). Investors have until October 27, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Defendants materially overstated LifeMD’s competitive position; (2) Defendants were reckless in raising LifeMD’s 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD’s RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, including Wegovy and Zepbound; and (3) as a result, defendants’ statements about LifeMD’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages.
 
If you purchased or otherwise acquired LifeMD shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.

The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in LifeMD. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: